Genfit SA (GNFT) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Genfit SA, a biopharmaceutical company, reported a significant revenue increase to €59.7 million for the first nine months of 2024, largely due to a milestone payment from Ipsen following the U.S. launch of Iqirvo for liver disease treatment. The company’s cash reserves also grew to €96.0 million as of September 2024, bolstered by its collaborative efforts in drug development. Genfit’s financial performance highlights its growing influence in the treatment of rare liver diseases.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
